176 related articles for article (PubMed ID: 23435646)
1. [Intraprostatic injection therapy in patients with benign prostatic syndrome].
Bschleipfer T; Bach T; Gratzke C; Madersbacher S; Oelke M
Urologe A; 2013 Mar; 52(3):354-8. PubMed ID: 23435646
[TBL] [Abstract][Full Text] [Related]
2. Intraprostatic injectables for male lower urinary tract symptoms: Reality or fiction?
Alcántara Montero A; Pascual Regueiro N
Actas Urol Esp (Engl Ed); 2018 Jun; 42(5):350-351. PubMed ID: 29398093
[No Abstract] [Full Text] [Related]
3. Emerging Minimally Invasive Treatment Options for Male Lower Urinary Tract Symptoms.
Magistro G; Chapple CR; Elhilali M; Gilling P; McVary KT; Roehrborn CG; Stief CG; Woo HH; Gratzke C
Eur Urol; 2017 Dec; 72(6):986-997. PubMed ID: 28734706
[TBL] [Abstract][Full Text] [Related]
4. Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
Denmeade SR; Egerdie B; Steinhoff G; Merchant R; Abi-Habib R; Pommerville P
Eur Urol; 2011 May; 59(5):747-54. PubMed ID: 21129846
[TBL] [Abstract][Full Text] [Related]
5. New intraprostatic injectables and prostatic urethral lift for male LUTS.
Magistro G; Stief CG; Gratzke C
Nat Rev Urol; 2015 Aug; 12(8):461-71. PubMed ID: 26195444
[TBL] [Abstract][Full Text] [Related]
6. Treatment of lower urinary tract symptoms: agents for intraprostatic injection.
Andersson KE
Scand J Urol; 2013 Apr; 47(2):83-90. PubMed ID: 23281591
[TBL] [Abstract][Full Text] [Related]
7. Re: Samuel R. Denmeade, Blair Egerdie, Gary Steinhoff, et al. Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 2011;59:747-54.
Cai T; Paolo DP; Malossini G
Eur Urol; 2011 Jun; 59(6):e33. PubMed ID: 21398021
[No Abstract] [Full Text] [Related]
8. Intraprostatic injections for lower urinary tract symptoms/benign prostatic enlargement treatment.
Lombardo R; Andersson KE; Tubaro A; De Nunzio C
Minerva Urol Nefrol; 2018 Dec; 70(6):570-578. PubMed ID: 30298711
[TBL] [Abstract][Full Text] [Related]
9. Patient-reported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic OnabotulinumtoxinA: 3-month results of a prospective single-armed cohort study.
Sacco E; Bientinesi R; Marangi F; Totaro A; D'Addessi A; Racioppi M; Pinto F; Vittori M; Bassi P
BJU Int; 2012 Dec; 110(11 Pt C):E837-44. PubMed ID: 22712582
[TBL] [Abstract][Full Text] [Related]
10. Prospective, randomized, double-blind, vehicle controlled, multicenter phase IIb clinical trial of the pore forming protein PRX302 for targeted treatment of symptomatic benign prostatic hyperplasia.
Elhilali MM; Pommerville P; Yocum RC; Merchant R; Roehrborn CG; Denmeade SR
J Urol; 2013 Apr; 189(4):1421-6. PubMed ID: 23142202
[TBL] [Abstract][Full Text] [Related]
11. Prostatic injection of botulinum toxin is not inferior to optimized medical therapy in the management of lower urinary tract symptoms due to benign prostatic hyperplasia: results of a randomized clinical trial.
Robert G; Descazeaud A; Karsenty G; Saussine C; Azzouzi AR; de la Taille A; Desgrandchamps F; Faix A; Fourmarier M; Georget A; Benard A; Barry Delongchamps N
World J Urol; 2018 Jun; 36(6):921-929. PubMed ID: 29383480
[TBL] [Abstract][Full Text] [Related]
12. Intraprostatic injection therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia.
Chapple C
Eur Urol; 2011 May; 59(5):755-6. PubMed ID: 21330048
[No Abstract] [Full Text] [Related]
13. A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease.
Williams SA; Merchant RF; Garrett-Mayer E; Isaacs JT; Buckley JT; Denmeade SR
J Natl Cancer Inst; 2007 Mar; 99(5):376-85. PubMed ID: 17341729
[TBL] [Abstract][Full Text] [Related]
14. Intraprostatic injections for lower urinary tract symptoms treatment.
Andersson KE
Curr Opin Urol; 2015 Jan; 25(1):12-8. PubMed ID: 25333915
[TBL] [Abstract][Full Text] [Related]
15. Intraprostatic Botulinum Neurotoxin Type A Injection for Benign Prostatic Hyperplasia-A Spotlight in Reality.
Hsu YC; Wang HJ; Chuang YC
Toxins (Basel); 2016 Apr; 8(5):. PubMed ID: 27128942
[TBL] [Abstract][Full Text] [Related]
16. Intraprostatic botulinum toxin type "A" injection in patients with benign prostatic hyperplasia and unsatisfactory response to medical therapy: A randomized, double-blind, controlled trial using urodynamic evaluation.
Totaro A; Pinto F; Pugliese D; Vittori M; Racioppi M; Foschi N; Bassi PF; Sacco E
Neurourol Urodyn; 2018 Mar; 37(3):1031-1038. PubMed ID: 28840969
[TBL] [Abstract][Full Text] [Related]
17. Urodynamic effects of transrectal intraprostatic Ona botulinum toxin A injections for symptomatic benign prostatic hyperplasia.
de Kort LM; Kok ET; Jonges TN; Rosier PF; Bosch JL
Urology; 2012 Oct; 80(4):889-93. PubMed ID: 22854138
[TBL] [Abstract][Full Text] [Related]
18. Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia.
Chuang YC; Chiang PH; Yoshimura N; De Miguel F; Chancellor MB
BJU Int; 2006 Nov; 98(5):1033-7; discussion 1337. PubMed ID: 16956361
[TBL] [Abstract][Full Text] [Related]
19. Outcome of Botulinum Toxin-A intraprostatic injection for benign prostatic hyperplasia induced lower urinary tract symptoms: A prospective multicenter study.
Moussa AS; Ragheb AM; Abdelbary AM; Ibrahim RM; El Adawy MS; Aref A; Assem A; Elfayoumy H; Elzawy F
Prostate; 2019 Aug; 79(11):1221-1225. PubMed ID: 31189024
[TBL] [Abstract][Full Text] [Related]
20. Intraprostatic Botulinum Toxin Type A injection in patients with benign prostatic enlargement: duration of the effect of a single treatment.
Silva J; Pinto R; Carvalho T; Botelho F; Silva P; Oliveira R; Silva C; Cruz F; Dinis P
BMC Urol; 2009 Aug; 9():9. PubMed ID: 19682392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
